{
    "2019-10-01": [
        [
            {
                "time": "2019-03-21",
                "original_text": "Biogen Stock Flailed On Alzheimer's Flop — Is This Biotech Stock A Buy Now?",
                "features": {
                    "keywords": [
                        "Biogen",
                        "Alzheimer's",
                        "Flop"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-11-15",
                "original_text": "Bausch shares slide after it sues Novartis’ unit Sandoz over blockbuster drug patents",
                "features": {
                    "keywords": [
                        "Bausch",
                        "shares",
                        "slide",
                        "Novartis",
                        "Sandoz",
                        "patents"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-11-15",
                "original_text": "Bausch files suit against Novartis unit Sandoz for infringing patents on Xifaxan 550 mg tablets",
                "features": {
                    "keywords": [
                        "Bausch",
                        "Novartis",
                        "Sandoz",
                        "Xifaxan",
                        "patents"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-09-26",
                "original_text": "Novartis and Microsoft join forces to develop drugs using AI",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Microsoft",
                        "AI",
                        "drugs"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "technology",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}